By Daphne Psaledakis, Simon Lewis and Elias Biryabarema WASHINGTON (Reuters) -About 1,000 doses of Gilead Sciences Inc's drug ...

Eswatini has become the first African country to receive lenacapavir, a twice-yearly HIV prevention injection that global ...

The Department of Health said the decision reflects its mandate to ensure that all citizens have access to safe, effective, ...

Indian pharmaceutical giants Dr. Reddy’s Laboratories and Hetero Labs are set to disrupt HIV prevention worldwide, announcing ...

Gilead Sciences, Inc. (Nasdaq: GILD) today announced the delivery of first shipments of lenacapavir – Gilead’s twice-yearly ...

Gilead Sciences has developed an industry-leading HIV portfolio in recent years with its megablockbuster daily treatment ...

The drug lenacapavir will be distributed to Eswatini and Zambia — the first step toward providing at least 2 million doses to ...

Tatenda Makoni is a Zimbabwean-born medical student at the Medical College of Wisconsin whose work bridges global health and ...

Lenacapavir is a twice-yearly injectable drug produced by Gilead Sciences that is aimed at preventing HIV infection. In 2024, ...

Discover how lenacapavir and bNAbs show high HIV-1 suppression, low resistance, and promising outcomes for future treatment ...

South Africa takes the lead in HIV prevention with a groundbreaking twice-a-year injection being added to the Essential Medicines List.

Activists have sharply criticised the US government’s move to exclude South Africa from receiving HIV prevention medication ...